New treatment aims to prevent hearing loss related to chemotherapy in pediatric patients.
- Norgine receives Swiss approval for Pedmarqsi
- Focus on preventing chemotherapy-induced hearing loss
- Targeting pediatric patients
Norgine has announced that its treatment Pedmarqsi has received approval from Swissmedic for preventing hearing loss in children undergoing chemotherapy with cisplatin. This condition is a significant concern, as cisplatin can often lead to ototoxicity, which results in hearing impairment. The approval represents a critical advancement in the management of side effects associated with cancer treatment in pediatric patients.
Pedmarqsi specifically addresses the risk of cisplatin-induced hearing loss, which is prevalent among children receiving this common chemotherapy drug. The treatment is designed to protect auditory function during cancer therapy, aiming to improve the quality of life for young patients who require such interventions. This approval underlines a growing recognition of the need for supportive treatments in oncology that mitigate long-term effects on health.
The approval from Swissmedic allows for the immediate availability of Pedmarqsi in Switzerland, providing an important option for healthcare providers and families. As research continues into the effects of chemotherapy, treatments like Pedmarqsi are key in enhancing overall treatment protocols for children battling cancer.
